Specialist Dr. Orcun Can

Specialist Dr. Orcun Can
Academic Title :
Specialist Dr.

Specialist Dr. Orçun Can is a medical oncologist at Liv Hospital Vadistanbul in Istanbul, Turkey. His clinical practice focuses on the diagnosis and systemic treatment of cancer, including chemotherapy, immunotherapy, and targeted therapies selected according to tumor type, stage, and relevant molecular characteristics.

His areas of expertise include breast cancer, lung cancer, gastrointestinal malignancies, genitourinary cancers, and gynecologic cancers. He is also interested in precision oncology, molecular biomarkers, and the clinical use of genomic testing and liquid biopsy when appropriate.

He graduated from Çukurova University Faculty of Medicine in 2009, completed his Internal Medicine specialization in 2014, and qualified in Medical Oncology in 2018. He undertook international academic training at the University of Oxford and Klinikum Oldenburg in Germany. His professional experience includes Acıbadem Maslak Hospital before joining Liv Hospital Vadistanbul in 2026.

Education and Academic Qualifications

  • Çukurova University Faculty of Medicine (2003–2009)
  • Istanbul Medeniyet University Göztepe Training and Research Hospital – Internal Medicine Specialist (2009–2014)
  • SBÜ Okmeydanı Training and Research Hospital – Medical Oncology Subspecialty (2015–2018)
  • Oxford University – Clinical Research Fellowship with Prof. David J. Kerr on Metastatic Colorectal Cancer (2015)
  • Klinikum Oldenburg – Clinical Research Fellowship with Prof. Claus-Henning Köhne & Prof. Frank Griesinger on Thoracic and Gastrointestinal Oncology (2017)

Areas of Interest

  • Breast cancer treatment in Turkey
  • Thoracic oncology and lung cancer treatment in Turkey
  • Gastrointestinal system cancers
  • Gynecological cancers
  • Urogenital system cancers
  • Immunotherapy and targeted therapies
  • Molecular oncology and precision medicine
  • Biomarkers and liquid biopsy
  • Kırklareli Pınarhisar State Hospital – Internal Medicine Specialist
  • SBÜ Okmeydanı Training and Research Hospital – Medical Oncology Subspecialty Resident
  • Nevşehir State Hospital – Medical Oncology Specialist
  • Prof. Dr. Cemil Taşcıoğlu City Hospital – Medical Oncology Specialist
  • Istinye University Liv Hospital – Medical Oncology Specialist
  • Acibadem Maslak Hospital – Medical Oncology Specialist
  • Liv Hospital Vadistanbul – Medical Oncology Specialist (2026–present)
  • European Society for Medical Oncology (ESMO)
  • American Society for Clinical Oncology (ASCO)
  • Turkish Medical Oncology Association (TTOD)
  • Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium (2023)
  • Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 2: Systemic Treatment (2025)
  • The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study (2022)
  • Factors Affecting Disease-Free Survival in Operated Nonmetastatic Gastrointestinal Stromal Tumors (2019)
  • Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study (2024)
Share :